These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

468 related articles for article (PubMed ID: 21629293)

  • 1. The productivity crisis in pharmaceutical R&D.
    Pammolli F; Magazzini L; Riccaboni M
    Nat Rev Drug Discov; 2011 Jun; 10(6):428-38. PubMed ID: 21629293
    [TBL] [Abstract][Full Text] [Related]  

  • 2. How to improve R&D productivity: the pharmaceutical industry's grand challenge.
    Paul SM; Mytelka DS; Dunwiddie CT; Persinger CC; Munos BH; Lindborg SR; Schacht AL
    Nat Rev Drug Discov; 2010 Mar; 9(3):203-14. PubMed ID: 20168317
    [TBL] [Abstract][Full Text] [Related]  

  • 3. R&D efficiency of leading pharmaceutical companies - A 20-year analysis.
    Schuhmacher A; Wilisch L; Kuss M; Kandelbauer A; Hinder M; Gassmann O
    Drug Discov Today; 2021 Aug; 26(8):1784-1789. PubMed ID: 34022459
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Translational regenerative medicine research: essential to discovery and outcome.
    Mason C; Dunnill P
    Regen Med; 2007 May; 2(3):227-9. PubMed ID: 17511558
    [No Abstract]   [Full Text] [Related]  

  • 5. R&D productivity rides again?
    Lendrem D; Senn SJ; Lendrem BC; Isaacs JD
    Pharm Stat; 2015; 14(1):1-3. PubMed ID: 25336017
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antibiotics in late clinical development.
    Fernandes P; Martens E
    Biochem Pharmacol; 2017 Jun; 133():152-163. PubMed ID: 27687641
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A lesson from Japan: research and development efficiency is a key element of pharmaceutical industry consolidation process.
    Shimura H; Masuda S; Kimura H
    Drug Discov Ther; 2014 Feb; 8(1):57-63. PubMed ID: 24647159
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Are the economics of pharmaceutical research and development changing?: productivity, patents and political pressures.
    Grabowski H
    Pharmacoeconomics; 2004; 22(2 Suppl 2):15-24. PubMed ID: 15660474
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discontinued drugs in 2010: oncology drugs.
    Williams R
    Expert Opin Investig Drugs; 2011 Nov; 20(11):1479-96. PubMed ID: 21955127
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Research and development productivity map: visualization of industry status.
    Shimura H; Masuda S; Kimura H
    J Clin Pharm Ther; 2014 Apr; 39(2):175-80. PubMed ID: 24438433
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The endless frontier? The recent increase of R&D productivity in pharmaceuticals.
    Pammolli F; Righetto L; Abrignani S; Pani L; Pelicci PG; Rabosio E
    J Transl Med; 2020 Apr; 18(1):162. PubMed ID: 32272953
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antibacterial R&D incentives.
    Laxminarayan R; Powers JH
    Nat Rev Drug Discov; 2011 Sep; 10(10):727-8. PubMed ID: 21959280
    [No Abstract]   [Full Text] [Related]  

  • 13. Should financial incentives be used to differentially reward 'me-too' and innovative drugs?
    Pekarsky B
    Pharmacoeconomics; 2010; 28(1):1-17. PubMed ID: 20014872
    [TBL] [Abstract][Full Text] [Related]  

  • 14. How to revive breakthrough innovation in the pharmaceutical industry.
    Munos BH; Chin WW
    Sci Transl Med; 2011 Jun; 3(89):89cm16. PubMed ID: 21715677
    [TBL] [Abstract][Full Text] [Related]  

  • 15. How should we support pharmaceutical innovation?
    Grootendorst P
    Expert Rev Pharmacoecon Outcomes Res; 2009 Aug; 9(4):313-20. PubMed ID: 19670991
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Precompetitive activity to address the biological data needs of drug discovery.
    Sidders B; Brockel C; Gutteridge A; Harland L; Jansen PG; McEwen R; Michalovich D; Seidel H; Weiss B; Williams-Jones B; Woodwark M
    Nat Rev Drug Discov; 2014 Feb; 13(2):83-4. PubMed ID: 24481293
    [No Abstract]   [Full Text] [Related]  

  • 17. Portfolio management in early stage drug discovery - a traveler's guide through uncharted territory.
    Betz UA
    Drug Discov Today; 2011 Jul; 16(13-14):609-18. PubMed ID: 21600301
    [TBL] [Abstract][Full Text] [Related]  

  • 18. What are the economic barriers of antibiotic R&D and how can we overcome them?
    Renwick M; Mossialos E
    Expert Opin Drug Discov; 2018 Oct; 13(10):889-892. PubMed ID: 30175625
    [No Abstract]   [Full Text] [Related]  

  • 19. Trends in risks associated with new drug development: success rates for investigational drugs.
    DiMasi JA; Feldman L; Seckler A; Wilson A
    Clin Pharmacol Ther; 2010 Mar; 87(3):272-7. PubMed ID: 20130567
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Overcoming the obstacles in the pharma/biotech industry: 2008 update.
    Graul AI; Revel L; Rosa E; Cruces E
    Drug News Perspect; 2009; 22(1):39-51. PubMed ID: 19209298
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.